Attributes | Values |
---|
rdf:type
| |
Description
| - V této randomizované studii III skupiny EORTC Leukemia Cooperative Group je analyzováno léčení pacientů s MDS s poruchou krvetvorby v 10-30%. (cs)
- In this randomized phase III study of the EORTC Leukemia Cooperative Group, treatemet of patients with myelodysplastic syndromes (MDS) with 10-30% bone marrow blasts and hematopoietic failure is analyzed.
- In this randomized phase III study of the EORTC Leukemia Cooperative Group, treatemet of patients with myelodysplastic syndromes (MDS) with 10-30% bone marrow blasts and hematopoietic failure is analyzed. (en)
|
Title
| - Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia
- Léčba pomocí nízkých dávek cytosinu arabinoside (LD-AraC) vs LD-AraC plus granulocytů / makrofágů vs LD-AraC plus interleukinu-3 u MDS u pacientů s vysokým rizikem vývoje akutní leukémie. (cs)
- Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia (en)
|
skos:prefLabel
| - Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia
- Léčba pomocí nízkých dávek cytosinu arabinoside (LD-AraC) vs LD-AraC plus granulocytů / makrofágů vs LD-AraC plus interleukinu-3 u MDS u pacientů s vysokým rizikem vývoje akutní leukémie. (cs)
- Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia (en)
|
skos:notation
| - RIV/00023736:_____/05:00007603!RIV09-MZ0-00023736
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00023736:_____/05:00007603
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - EORTC Leukemia Cooperative Group; MDS (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - GB - Spojené království Velké Británie a Severního Irska
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Neuwirtová, R.
- Čermák, Jaroslav
- Fenaux, P.
- Amadori, S.
- Suciu, S.
- Zwierzina, H.
- De Witte, T. M.
- Willemze, R.
- Beksac, M.
- Harousseau, J.
- Loeffler-Ragg, J.
- Nuessler, V.
- Solbu, G.
|
http://linked.open...ain/vavai/riv/wos
| |
issn
| |
number of pages
| |
is http://linked.open...avai/riv/vysledek
of | |